Discover Our Latest News

FDA Approves Enhertu for Two New HER2-Positive Early Breast Cancer Indications

FDA Approves Sonrotoclax as First BCL2 Inhibitor for R/R Mantle Cell Lymphoma

Perioperative Durvalumab Regimen Improves EFS and OS in Muscle-Invasive Bladder Cancer

FDA Approves First All-Oral INQOVI Plus Venetoclax Regimen for Newly Diagnosed AML

FDA Grants RMAT Designation to RZ-001, a Novel RNA Therapy for Hepatocellular Carcinoma

FDA Approves Bizengri as First Targeted Therapy for NRG1 Fusion+ Cholangiocarcinoma

FDA Grants Fast Track Designation to RPTR-1-201 for Advanced Triple- Breast Cancer

PHERGain Data Support Chemo-Free Treatment With 90% Five-Year RFS in Breast Cancer

FDA Grants Fast Track Designation to Dubodencel for Advanced Cutaneous Melanoma

Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer

FDA Accepts IBTROZI sNDA After Durable Long-Term Benefit in Advanced ROS1+ Lung Cancer

ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit

FDA ODAC Backs Truqap Combination for PTEN-Deficient Metastatic Prostate Cancer

Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk

Zeta Navigation System Gains FDA Clearance for Brain Tumor Biopsy and Neurosurgery

FDA Approves Vepdegestrant, First PROTAC Therapy for ESR1+ ER+/HER2- Breast Cancer

SUNRISE-II Trial Begins Evaluating Ultrasound-Guided HIFU Ablation for Pancreatic Cancer

Restoring Proteostasis May Boost T Cell Function and Open a New Route for Immunotherapy

OPTIMAL Data Support TLX597-Tx as a Next-Gen Radioligand Therapy in Prostate Cancer

AidaBREAST Gains FDA Breakthrough Status for Personalized Radiotherapy in Breast Cancer

Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma

Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer

Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer

Early CAR T-Cell Intervention Shows Disease-Eradication Potential in High-Risk Myeloma

World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer

Long-Term Data Show Taletrectinib Delivers High Response Rates in ROS1+ NSCLC

FDA-Cleared Utepreva Device Aims to Improve Early Endometrial Cancer Detection

Opaganib Shows Dual Preclinical Promise in Neuroblastoma and Triple- Breast Cancer

Ozekibart Shows Encouraging Late-Line Activity in Metastatic Colorectal Cancer

FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma